Absci Corporation (ABSI) Stock

Absci Corporation (ABSI) is a Technology stock trading at $8.79 (as of 2026-09-02), with a market capitalization of $1.37B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Absci Corporation is engaged in drug and target discovery, providing biologic drug candidate programs and production cell lines for partners. It offers an integrated platform that connects discovery activities with cell line development as part of a unified workflow for biologics in the United States.

Understand Absci Corporation: how it makes money

Absci uses an integrated drug-creation platform to develop biologic candidates and production cell lines, earning fees from pharmaceutical partners for discovery and cell-line development work. The model is entirely partnership-contingent, so value hinges on pipeline progression and new partner agreements rather than recurring product sales.

Absci earns no product revenue; all income depends on pharma partners paying technology and milestone fees as its platform-derived candidates advance, meaning cash flow is lumpy and inextricably tied to each partner program's clinical timeline.

Business quality (Unprofitable): Pre-revenue-stage platform company with an operating margin of -10742%, indicating heavy R&D outlay against negligible income; sustainability depends entirely on securing and progressing partner programs.

Bull case

  • Front-Loaded Platform Investment: The operating margin of -10742% reflects heavy R&D spending characteristic of a biotech platform still in the development and clinical-validation phase, a stage before partner milestone income begins to offset burn.

Bear case

  • Extreme Cash Burn, No Offset: An operating margin of -10742% against effectively zero revenue means the company is consuming capital at a rate with no commercial counterbalance, creating material dilution and funding risk if partner programs do not deliver milestone payments on schedule.
Valuation — source: SEC EDGAR (first-party)
Price$8.79
Market Cap$1.37B
Price / Book5.57
Price / Sales878.40
FCF Yield-6.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.80M
Net Margin-4113.7%
Revenue Growth (YoY)-46.4%
EPS Growth (YoY)-12.5%
FCF Growth (YoY)215.3%
Financial Health — source: SEC EDGAR
Altman Z-Score25.03 (safe)
Valuation vs Sector & Industry
Sector P/E (Technology)31.8
Industry P/E (Business Services)28.3
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($67.65M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryBusiness Services
CEOSean McClain
Employees156
CountryUS
IPO Date2022-03-22

Related Companies (Business Services; 8 comparable business services companies)

  • iSpecimen Inc. (ISPC)
  • OneMedNet Corporation (ONMD)
  • bioAffinity Technologies, Inc. (BIAF)
  • OmniAb, Inc. (OABI)
  • BNB Plus Corp. (BNBX)
  • 20/20 Biolabs, Inc. Common Stock (AIDX)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Biomerica, Inc. (BMRA)
ABSI earnings history · ABSI institutional & insider holders · ABSI KPIs & operating metrics · ABSI financials · ABSI investor presentations & press releases · ABSI SEC filings · ABSI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.